Study of the Efficacy of the Treatment of Sleep Apnea Syndrome by CPAP in Pharmacoresistant Epilepsy

Study of the Efficacy of the Treatment of Sleep Apnea Syndrome by CPAP in Pharmacoresistant Epilepsy

Study of the Efficacy of the Treatment of Sleep Apnea Syndrome by CPAP in Pharmacoresistant Epilepsy. The primary goal is to evaluate the efficacity after 3 months of obstructive sleep apnea syndrome treatment by CPAP on the epilepsy seizures frequency.

Inclusion Criteria:

• Male or female age ≥ 18.
• Patient suffering of pharmacoresistant epilepsy.
• Frequency of epilepsy crisis : minimum 4 per month.
• Antiepileptic drug on a stable dose for at least 2 months.
• SA-SDQ score ≥ 25.
• Written informed consent obtained.
• Patient affiliated with a social security regimen.

Exclusion Criteria:

• Pregnant females (female subjects who are lactating are not excluded).
• Anterior CPAP treatment.
• Central apnea >20% during the initial polysomnography.
• Mental retardation or severe cognitive impairment.
• Presence of pseudo-crisis.